title: Adjuvant trastuzumab: does time really matter?
authors.affiliation: Washington Cancer Institute, MedStar Washington Hospital Center, Washington, District of Columbia 20010, USA. sandra.m.swain@medstar.net
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human